Regentatlantic Capital LLC Buys 3,283 Shares of Johnson & Johnson (JNJ)

Regentatlantic Capital LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 169,430 shares of the company’s stock after purchasing an additional 3,283 shares during the period. Johnson & Johnson accounts for about 2.0% of Regentatlantic Capital LLC’s investment portfolio, making the stock its 3rd biggest holding. Regentatlantic Capital LLC’s holdings in Johnson & Johnson were worth $22,414,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in JNJ. Lenox Wealth Advisors Inc. grew its holdings in Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares during the period. Ullmann Financial Group Inc. bought a new stake in Johnson & Johnson during the first quarter valued at about $186,000. Taylor Wealth Management Partners grew its holdings in Johnson & Johnson by 19.8% during the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares during the period. Finally, Puplava Financial Services Inc. bought a new stake in Johnson & Johnson during the second quarter valued at about $202,000. 65.90% of the stock is owned by institutional investors and hedge funds.

In related news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

Several analysts have issued reports on the company. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, July 21st. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a report on Friday, July 21st. BTIG Research lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target for the company. in a report on Friday, July 21st. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Finally, Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a report on Monday, September 18th. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $136.02.

ILLEGAL ACTIVITY NOTICE: “Regentatlantic Capital LLC Buys 3,283 Shares of Johnson & Johnson (JNJ)” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/10/11/regentatlantic-capital-llc-buys-3283-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson (JNJ) traded up 2.05% during midday trading on Wednesday, hitting $136.64. The company had a trading volume of 3,928,192 shares. The firm has a market capitalization of $366.74 billion, a P/E ratio of 22.96 and a beta of 0.78. The company has a 50 day moving average price of $132.27 and a 200 day moving average price of $130.03. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the previous year, the firm posted $1.74 EPS. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. Equities research analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.51%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply